Fulgent Genetics, Inc.: Form 10-K for the period ended Dec 31, 2022
Filed with the SEC on Feb 28, 2023 and accepted by EDGAR at Feb 28, 2023, 16:49 ET.
Sections
The sections of this filing are being extracted from EDGAR and appear here in about a minute. Meanwhile, read the original on sec.gov. The main document on sec.gov.
Figures reported in this filing
Standardized line items from the XBRL in this filing, for the period ended 2022-12-31. Comparative periods it repeats are left out.
| Line item | Period | Value | XBRL concept |
|---|---|---|---|
| Revenue | 3 months2022-10-01 to 2022-12-31 | $67.7m | us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax |
| Revenue | 12 months2022-01-01 to 2022-12-31 | $619.0m | us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax |
| Cost of revenue | 3 months2022-10-01 to 2022-12-31 | $54.7m | us-gaap:CostOfRevenue |
| Cost of revenue | 12 months2022-01-01 to 2022-12-31 | $252.1m | us-gaap:CostOfRevenue |
| Gross profit | 3 months2022-10-01 to 2022-12-31 | $13.0m | us-gaap:GrossProfit |
| Gross profit | 12 months2022-01-01 to 2022-12-31 | $366.9m | us-gaap:GrossProfit |
| Research and development | 3 months2022-10-01 to 2022-12-31 | $8.5m | us-gaap:ResearchAndDevelopmentExpense |
| Research and development | 12 months2022-01-01 to 2022-12-31 | $28.9m | us-gaap:ResearchAndDevelopmentExpense |
| Operating income | 3 months2022-10-01 to 2022-12-31 | −$36.6m | us-gaap:OperatingIncomeLoss |
| Operating income | 12 months2022-01-01 to 2022-12-31 | $178.5m | us-gaap:OperatingIncomeLoss |
| Interest expense | 12 months2022-01-01 to 2022-12-31 | $346.0k | us-gaap:InterestExpense |
| Income tax | 3 months2022-10-01 to 2022-12-31 | −$9.4m | us-gaap:IncomeTaxExpenseBenefit |
| Income tax | 12 months2022-01-01 to 2022-12-31 | $42.1m | us-gaap:IncomeTaxExpenseBenefit |
| Net income | 3 months2022-10-01 to 2022-12-31 | −$23.8m | us-gaap:NetIncomeLoss |
| Net income | 12 months2022-01-01 to 2022-12-31 | $143.4m | us-gaap:NetIncomeLoss |
| Diluted shares (weighted) | 12 months2022-01-01 to 2022-12-31 | 30,964,000 shares | us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding |
| Operating cash flow | 12 months2022-01-01 to 2022-12-31 | $253.5m | us-gaap:NetCashProvidedByUsedInOperatingActivities |
| Capital expenditure | 12 months2022-01-01 to 2022-12-31 | $18.8m | us-gaap:PaymentsToAcquirePropertyPlantAndEquipment |
| Share repurchases | 12 months2022-01-01 to 2022-12-31 | $74.3m | us-gaap:PaymentsForRepurchaseOfCommonStock |
| Cash and equivalents | At period end2022-12-31 | $79.5m | us-gaap:CashAndCashEquivalentsAtCarryingValue |
| Current assets | At period end2022-12-31 | $627.9m | us-gaap:AssetsCurrent |
| Total assets | At period end2022-12-31 | $1.39bn | us-gaap:Assets |
| Current liabilities | At period end2022-12-31 | $88.1m | us-gaap:LiabilitiesCurrent |
| Total liabilities | At period end2022-12-31 | $116.2m | us-gaap:Liabilities |
| Shareholders' equity | At period end2022-12-31 | $1.27bn | us-gaap:StockholdersEquity |
Source: SEC EDGAR, the filing index for accession 0000950170-23-005178. Last ingested by Listed: Oct 24, 2026, 15:07 ET. Listed shows no prices and gives no investment advice.